Nanoparticle Albumin-Bound Rapamycin and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Advanced Soft Tissue Sarcoma
- Locally Advanced Soft Tissue Sarcoma
- Metastatic Soft Tissue Sarcoma
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
OUTLINE: This is a phase I, dose-escalation study of nanoparticle albumin-bound rapamycin followed by a phase II study. Participants receive ABI-009 intravenously (IV) on days 1 and 8 and pazopanib hydrochloride orally (PO) daily on days 1-21. Cycles repeat every 21 days until unequivocal clinical d...
OUTLINE: This is a phase I, dose-escalation study of nanoparticle albumin-bound rapamycin followed by a phase II study. Participants receive ABI-009 intravenously (IV) on days 1 and 8 and pazopanib hydrochloride orally (PO) daily on days 1-21. Cycles repeat every 21 days until unequivocal clinical disease progression, unacceptable toxicity, or until in the opinion of the investigator the patient is no longer benefiting from therapy, or at the patient's discretion. After completion of study treatment, participants are followed up at 30 days, then every 12 weeks.
Tracking Information
- NCT #
- NCT03660930
- Collaborators
- National Cancer Institute (NCI)
- Aadi, LLC
- Investigators
- Principal Investigator: Lee Cranmer, MD Fred Hutch/University of Washington Cancer Consortium
Get Well Soon